Scientists are hailing what they believe to be a historic breakthrough in the fightback against the degenerative brain disease Alzheimer’s, after an antibody therapy known as lecanamab proved to slow the onset of the condition during clinical trials.
The development follows decades of failed attempts to find a way to halt its progress and has inspired hope among experts that it could eventually pave the way for treatments that might ultimately lead to a cure.
